

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1502
Examiner: Gollamudi S. Kishore

In re PATENT REISSUE APPLICATION of:

Patentees	:	Patrick L. AHL et al.)	
)	
U.S. Patent No.	:	5,662,930)	
)	
Issued	:	September 2, 1997)	
)	
Reissue)	PAPER UNDER
Application No.	:	TBD)	RULE 37 C.F.R 1.607
)	
Reissue Filed	:)	
)	
For	:	REDUCTION OF LIPOSOME-INDUCED)	
		ADVERSE PHYSIOLOGICAL REACTIONS)	
)	
Attorney Docket	:	31839-150675)	
		(client ref.: TLC 201C RIS))	

September 1, 1999

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

The above identified Reissue application is based on U.S. Patent No. 5,662,930, which issued September 2, 1999. That U.S. Patent No. 5,662, 930 issued on an application filed on May 4, 1995 (which in turn is a division of U.S. Serial No. 247,053, filed May 20, 1994, which is a continuation-in-part of U.S. Serial No. 207,651, filed March 7, 1994 and now abandoned, which in turn is a continuation -in-part of U.S. Serial No. 065,928, filed May 21, 1993 and now abandoned.)

Claims in the reissue application appear to be directed to the same patentable invention as those in U.S. Patent No. 5,847,422 which has a PCT filing date of May 9, 1996, a 35 USC 102(e) date of January 27, 1998 and a priority date of May 10, 1995.

Presentation of proposed Count

Count: A preparation for reducing adverse physiological reaction comprising an anti-inflammatory agent and a pharmaceutical agent which induces said adverse physiological effect.

Claims in the Patent 5847422 corresponding to the Count

Claims 1-9 of the U.S. 5847422 correspond to the proposed count.

Claims in the application corresponding to the Count

At least Claims 18-32 of the application correspond to the count.

Claims 18-32 are set forth below:

18. A method of treating an animal with a bioactive agent comprising administering to said animal an anti-inflammatory agent and a liposome composition, wherein said liposome composition induces an adverse physiological reaction in said animal; and reducing said adverse physiological reaction.

19. The method of Claim 18, wherein said adverse physiological reaction is a blood pressure drop.

20. The method of Claim 19, wherein the anti-inflammatory agent is indomethacin.

21. The method of Claim 18, wherein the anti-inflammatory agent is a steroid.

22. The method of Claim 18, wherein the anti-inflammatory agent is non-steroidal.

23. A method of treating an animal with a bioactive agent comprising administering to said animal a composition comprising a liposome and an anti-inflammatory agent,
wherein said liposome composition induces an adverse physiological reaction in said animal; and
reducing said adverse physiological reaction.

24. A method of treating an animal to reduce adverse physiological reaction in said animal, comprising
administering to said animal a composition comprising a liposome and a bioactive agent;
wherein said liposome composition induces an adverse physiological reaction in said animal;
administering an anti inflammatory agent, to said animal; and
reducing said adverse physiological reaction.

25. A liposome composition comprising a liposome and a bioactive agent which is an anti-inflammatory agent.

26. The composition of Claim 25, wherein the anti-inflammatory agent is indomethacin.

27. The composition of Claim 25, wherein the anti-inflammatory agent is a steroid.

28. The composition of Claim 25, wherein the anti-inflammatory agent is non-steroidal.

29. A liposome composition comprising a liposome and a bioactive agent which is a contrast agent, in combination with an anti-inflammatory agent.

30. The composition of Claim 29, wherein the anti-inflammatory agent is indomethacin.

31. The composition of Claim 29, wherein the anti-inflammatory agent is a steroid.

32. The composition of Claim 29, wherein the anti-inflammatory agent is non-steroidal.

Support in application for Claims corresponding to the Count

Claims 18, 23 and 24

The recitations in claims 18, 23 and 24, comprising the combination of a liposome and a bioactive agent, are supported by column 7, lines 14-16 and column 7, line 27, respectively. The recitation concerning an adverse physiological reaction inducing liposome is found at column 2, line 9, et seq., and column 4, lines 28-33. The recitation concerning the combination of the liposome composition with the anti-inflammatory is supported by column 3, lines 8-25; column 7, line 27; and column 12, line 1, et seq., as well as Example 4 at column 21.

Reducing the adverse physiological reaction is supported by the specification at column 1, line 20 and by e.g. column 14, lines 60, et seq.

Claim 19

The recitation concerning blood pressure drop is supported by column 14, line 60, et seq.

Claims 20, 26 and 30

The recitation of the anti-inflammatory agent indomethacin is supported by Example 4 and by column 12, line 19.

Claims 21, 27, 31

Claim 21 recitation concerning a steroid as an anti-inflammatory agent is supported by column 12, line 17.

Claim 22, 28 and 32

Claim 22 recitation concerning a non-steroid as an anti-inflammatory agent is at column 12, line 19.

Claim 25


The recitations in claim 25 comprising the combination of a liposome and a bioactive agent are supported by column 7, lines 14-16 and column 7, line 27, respectively.

Claim 29

The recitations in claim 29 comprising the combination of a liposome and a bioactive agent are supported by column 7, lines 14-16 and column 7, line 27, respectively.

Should any fee be required, please charge the same to our deposit account #19-3700, and advise us accordingly.

Respectfully submitted,



Marina V. Schneller

Registration No. 26,032

VENABLE

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 962-4800

Telefax: (202) 962-8300

MVS:rei
DC2-157599